Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

Thinking Outside the Box: Innate- and B Cell-Memory Responses as Novel Protective Mechanisms Against Tuberculosis

(2020) José Alberto Choreño-Parra et al.   Frontiers in Immunology

Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment

(2020) Uma Shanmugasundaram et al.   JCI Insight

A Two-Step Orthogonal Chromatographic Process for Purifying the Molecular Adjuvant QS-21 with High Purity and Yield

(2020) Yizhi Qi et al.   JOURNAL OF CHROMATOGRAPHY A

First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria

(2019) Benjamin Mordmüller et al.   CLINICAL INFECTIOUS DISEASES

Designing tuberculosis vaccine efficacy trials – lessons from recent studies

(2019) Ann M. Ginsberg   Expert Review of Vaccines

Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review

(2019) Marie-Aleth Lacaille-Dubois   PHYTOMEDICINE

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model

(2019) Kee Woong Kwon et al.   Scientific Reports

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

(2019) Dereck R. Tait et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial

(2018) Adam Penn-Nicholson et al.   Lancet Respiratory Medicine

Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette–Guérin-Vaccinated Adults

(2018) Robert A. van den Berg et al.   Frontiers in Immunology

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

(2018) Rhea N. Coler et al.   npj Vaccines

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis

(2018) Olivier Van Der Meeren et al.   NEW ENGLAND JOURNAL OF MEDICINE

The adjuvant GLA-AF enhances human intradermal vaccine responses

(2018) Darrick Carter et al.   Science Advances

Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity

(2017) Margherita Coccia et al.   npj Vaccines

Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical Cartridge

(2016) Lucien Barnes V et al.   AAPS PHARMSCITECH

A Functional Role for Antibodies in Tuberculosis

(2016) Lenette L. Lu et al.   CELL

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

(2016) Arnaud M. Didierlaurent et al.   Expert Review of Vaccines

Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults

(2016) Marilia Santini-Oliveira et al.   VACCINE

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction

(2016) Natasha Dubois Cauwelaert et al.   PLoS One

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate

(2015) Susan L. Baldwin et al.   Clinical and Vaccine Immunology

B cells and antibodies in the defense againstMycobacterium tuberculosisinfection

(2015) Jacqueline M. Achkar et al.   IMMUNOLOGICAL REVIEWS

Vaccination Produces CD4 T Cells with a Novel CD154–CD40-Dependent Cytolytic Mechanism

(2015) Rhea N. Coler et al.   JOURNAL OF IMMUNOLOGY

Landmark green light for Mosquirix malaria vaccine

(2015) Chris Morrison   NATURE BIOTECHNOLOGY

Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette–Guérin vaccination against tuberculosis

(2014) I Abubakar et al.   HEALTH TECHNOLOGY ASSESSMENT

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization

(2014) Mark T. Orr et al.   JOURNAL OF CONTROLLED RELEASE

Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells

(2014) Arnaud M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

The role of B cells and humoral immunity in Mycobacterium tuberculosis infection

(2014) John Chan et al.   SEMINARS IN IMMUNOLOGY

Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults

(2013) Cheryl L. Day et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

In vitro evaluation of TLR4 agonist activity: Formulation effects

(2013) Ayesha Misquith et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis

(2013) Mark T. Orr et al.   JOURNAL OF CONTROLLED RELEASE

Adjuvants for human vaccines

(2012) Carl R Alving et al.   CURRENT OPINION IN IMMUNOLOGY

The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

(2012) S. L. Baldwin et al.   JOURNAL OF IMMUNOLOGY

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

(2011) Rhea N. Coler et al.   PLoS One

A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis

(2010) S. Bertholet et al.   Science Translational Medicine

Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants

(2009) AC Hesseling   BULLETIN OF THE WORLD HEALTH ORGANIZATION